Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | PRT1419 |
Trade Name | |
Synonyms | PRT 1419|PRT-1419 |
Drug Descriptions |
PRT1419 is an inhibitor of myeloid cell leukemia 1 (MCL1) that blocks inactivation of pro-apoptotic proteins by Mcl1, which may lead to apoptosis of tumor cells overexpressing Mcl1 (NCI Drug Dictionary). |
DrugClasses | MCL1 Inhibitor 18 |
CAS Registry Number | NA |
NCIT ID | C176964 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Belzutifan + PRT1419 | Belzutifan PRT1419 | 0 | 0 |
Cabozantinib + PRT1419 | Cabozantinib PRT1419 | 0 | 0 |
Everolimus + PRT1419 | Everolimus PRT1419 | 0 | 0 |
Pazopanib + PRT1419 | PRT1419 Pazopanib | 0 | 0 |
PRT1419 | PRT1419 | 0 | 3 |
PRT1419 + Sunitinib | PRT1419 Sunitinib | 0 | 0 |